Elanco

FDA approves Zenrelia, a once-daily JAK inhibitor for dogs with allergic and atopic dermatitis, entering the $1.7 billion global canine dermatology market. Zenrelia showed 77% of dogs achieving clinical remission of itch compared to 53% with Apoquel in a head-to-head study. Elanco now takes orders for Zenrelia in the U.S., with shipments expected soon.

Elanco Animal Health Incorporated

The Animal Biotechnology Market is projected to grow from USD XX billion in 2023 to USD XX billion by 2031, at a CAGR of XX% (2024-2031). The market is segmented by product, application, animal type, and end-use, with key players including Zoetis, Boehringer Ingelheim, Biogénesis Bagó, and Merck & Co. The report provides insights into market size, growth, revenue, and competitive landscape, focusing on regions like North America, Europe, and Asia Pacific.